CELLINK has entered into an agreement to acquire MatTek, the global leader in in-vitro technology and alternative drug testing models

Share on facebook
Share on twitter
Share on linkedin

CELLINK AB (publ) (“CELLINK”) has entered into an agreement with the shareholders of MatTek Corporation (“MatTek”), an American company focusing on advanced in-vitro technology for clinical and pre-clinical studies offering in-vitro human tissue model innovation, cell isolation and cell culture, to acquire all outstanding shares in MatTek for a purchase price on a cash- and debt-free basis of $68 million (the “Acquisition”). Twenty percent of the purchase price will be paid in newly issued shares of series B in CELLINK (the “Consideration Shares”) and the remaining purchase price in cash. CELLINK’s Board of Directors will resolve to issue the Consideration Shares in accordance with the authorization from the Extraordinary General Meeting held on December 17, 2020.

Read full press release

More News

BIO CELLX
BIO CELLX
See a video on how the system works in practice

Get the link to the full video below, or watch the abridged version on our Youtube channel.

BIO X6 - Demo

BIO X6 - Demo